In Reply We agree with Dr Nightingale that equal access to information is essential for fairness in expanded access or other compassionate use programs.
Nightingale suggests several possible mechanisms for increasing patient access to information. We look forward to working with others to consider their ramifications and means for effective and efficient implementation.
Rosenblatt M, Kuhlik B. FDA Expanded Access Programs for Experimental Medicines—Reply. JAMA. 2015;314(12):1296. doi:10.1001/jama.2015.9728
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: